Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by CravenRaven101on May 10, 2011 4:28pm
307 Views
Post# 18556028

maybe...

maybe...I should have said that the BIG jump could be underway right now as well... IT very well might be... in which case... I would be left standing on the sidelines... BUT I was looking for a ground floor opportunity when I found this one...

So... IF the jump happens tomorrow... I will miss out...IF it happens next year... I could end up missing out then...

I spotted a stock... it was trading at under a dime... I thought it had promise... BUT I waited... it made it to 17 cents... and I waited... it hit 26 cents... and I bought... It went to 47 cents... and I held... today... a year later... it's trading at 26 cents... I have hopes... hopes it will make it to 3 bucks... in 2- 3 years...

I do NOT offer advice... I offer my opinion... IT is mine... git yer own... :oP....
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities